Altimmune, Inc. ALT
2.01 USD +0.03 (+1.78%)
Nov 6, 2026, 1:52 PM EST
1.95 Day range 2.03
1.91 52-week range 6.44
- YTD
- -44.46%
- 1 year
- -49.11%
- Market cap
- 390.98M
- Revenue (ttm)
- 52.00K
- EPS (ttm)
- -0.76
- Shares out
- 71.12M
- Forward P/E
- -5.14
- YTD return
- -44.46%
- 1-year return
- -49.11%
- Volume
- 1.43M
- Avg volume
- 3.93M
- Open
- 1.98
- Previous close
- 1.97
- Day's range
- 1.95 – 2.03
- 52-week range
- 1.91 – 6.44
- Beta
- 0.07
- Analysts
- Buy
- Price target
- 22.86 (+1040.0%)
5D -0.08 (-3.83%)
Key statistics
- Enterprise value
- 449.17M
- PEG ratio
- 0.00
- Price / sales
- 10326.74
- Price / book
- 4.03
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -98.60%
- Free cash flow
- -45.63M
- Total cash
- 139.38M
- Total debt
- 1.77M
- Return on equity
- -72.96%
- Short % of float
- 33.04%
- 50-day average
- 7.91
- 200-day average
- 7.41
Analyst view
Consensus: buy
Buy
Price target (mean) 22.86 +1040.0% upside
Now 2.01
- Target (low)
- 12.00
- Target (mean)
- 22.86
- Target (high)
- 28.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy3
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.24.
Financials — quick view
ALT Revenue — quarterly 0
ALT Net income — quarterly -22.82M
ALT EPS — quarterly -0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.36 | -0.32 | +0.04 | +11.11% |
| Aug 8, 2024 | Jun 1, 2024 | -0.34 | -0.35 | -0.01 | -2.94% |
| May 9, 2024 | Mar 1, 2024 | -0.36 | -0.34 | +0.02 | +5.56% |
| Mar 27, 2024 | Dec 1, 2023 | -0.35 | -0.33 | +0.02 | +5.71% |
| Nov 7, 2023 | Sep 1, 2023 | -0.40 | -0.39 | +0.01 | +2.50% |
| Aug 10, 2023 | Jun 1, 2023 | -0.44 | -0.32 | +0.12 | +27.27% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | UBS | init | — | Buy |
| Aug 12, 2024 | B. Riley Securities | reit | Buy | Buy |
| Jun 25, 2024 | B. Riley Securities | reit | Buy | Buy |
| Jun 21, 2024 | Piper Sandler | main | Overweight | Overweight |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- altimmune.com
News
Altimmune To Present Phase 2 RECLAIM Results For Pemvidutide In Alcohol Use Disorder At AASLD Liver Meeting; FDA End-Of-Phase 2 Meeting Set For December 
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17 
9 Health Care Stocks Whale Activity In Today’s Session 
Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate 
Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Altimmune Says Topline Data From RECLAIM Phase 2 Trial Of Pemvidutide For Alcohol Use Disorder Met Its Primary Endpoint Showing Statistically Significant Reduction In Heavy Drinking Days Vs. Placebo
- Leerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $10
Altimmune Announces New Data From Phase 2b Trial Of Pemvidutide Showing Improvements Across Multiple Non-Invasive Tests Of Metabolic Dysfunction-Associated Steatoheaptitis Activity And Fibrosis.
Your note
Sign in to keep a note on ALT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DRUTZ DAVID J | Director | Sale | Aug 18, 2024 | 0 |
| EISENSTADT RICHARD I | Chief Financial Officer | Stock Award(Grant) | Jan 30, 2024 | 45,012 |
| GARG VIPIN K. | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 1, 2024 | 292,028 |
| HARRIS MATTHEW SCOTT | Officer | Stock Award(Grant) | Jul 30, 2024 | 55,119 |
| JORDT RAYMOND M | Officer | Stock Award(Grant) | Jul 30, 2024 | 14,660 |
| ROBERTS M SCOT | Officer | Stock Award(Grant) | Jul 30, 2024 | 43,325 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.69% | 5,466,094 | 41.27M | Sep 29, 2024 |
| Vanguard Group Inc | 7.01% | 4,983,858 | 37.63M | Sep 29, 2024 |
| Ameriprise Financial, Inc. | 5.45% | 3,876,044 | 29.26M | Sep 29, 2024 |
| State Street Corporation | 4.80% | 3,413,827 | 25.77M | Sep 29, 2024 |
| Tang Capital Management, LLC | 3.87% | 2,750,000 | 20.76M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.35% | 1,668,004 | 12.59M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.63% | 2,584,274 | 19.51M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.57% | 1,830,974 | 13.82M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.52% | 1,790,759 | 13.52M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.54% | 1,098,135 | 8.29M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.02% | 727,869 | 5.50M | Aug 30, 2024 |
| Fidelity Strategic Advisors Small-Mid Cap Fund | 0.57% | 406,082 | 3.07M | Jul 30, 2024 |